Form 4: Coya Therapeutics CFO David Snyder Acquires Shares in Open Market Transaction

Coya Therapeutics' Chief Financial Officer, David Snyder, purchased 1,800 shares of common stock at a price of $7.1858 per share on November 14, 2024.

Summary

• David Snyder, the Chief Financial Officer of Coya Therapeutics, Inc., acquired 1,800 shares of the company's common stock on November 14, 2024.
• The purchase was made at a price of $7.1858 per share.
• Following this transaction, Mr. Snyder directly owns a total of 8,800 shares of Coya Therapeutics common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the purchase of shares by an officer is generally seen as a positive sign, it's a routine transaction and doesn't indicate a major shift in the company's outlook.

Positives

• The purchase of shares by a company officer can be seen as a positive sign of confidence in the company's future prospects.

Industry Context

This is a routine disclosure of an insider transaction, which is common in publicly traded companies. It provides transparency into the trading activities of company officers.

Comparison to Industry Standards

• Insider trading disclosures are a standard practice for publicly listed companies, and this transaction is consistent with regulatory requirements.
• Similar transactions are regularly reported by officers and directors of other companies in the biotechnology sector.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment, as it indicates confidence from a company officer.

Key Dates

Keywords

Coya Therapeutics, David Snyder, insider trading, share purchase, common stock, SEC Form 4, officer transaction